期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 131, 期 4, 页码 848-856出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2010.346
关键词
-
类别
资金
- NCRR [1 S10 RR16851]
- DEBRA International
- Epidermolysis Bullosa Research Fund
- University of Minnesota Academic Health Center
- Liao Family Epidermolysis Bullosa Fund
- Sarah Rose Mooreland Epidermolysis Bullosa Fund
- Children's Cancer Research Fund, Minneapolis, Minnesota
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited blistering skin disorder caused by mutations in the COL7A1 gene-encoding type VII collagen (Col7), the major component of anchoring fibrils at the dermal-epidermal junction. Individuals with RDEB develop painful blisters and mucosal erosions, and currently, there are no effective forms of therapy. Nevertheless, some advances in patient therapy are being made, and cell-based therapies with mesenchymal and hematopoietic cells have shown promise in early clinical trials. To establish a foundation for personalized, gene-corrected, patient-specific cell transfer, we generated induced pluripotent stem (iPS) cells from three subjects with RDEB (RDEB iPS cells). We found that Col7 was not required for stem cell renewal and that RDEB iPS cells could be differentiated into both hematopoietic and nonhematopoietic lineages. The specific epigenetic profile associated with de-differentiation of RDEB fibroblasts and keratinocytes into RDEB iPS cells was similar to that observed in wild-type (WT) iPS cells. Importantly, human WT and RDEB iPS cells differentiated in vivo into structures resembling the skin. Gene-corrected RDEB iPS cells expressed Col7. These data identify the potential of RDEB iPS cells to generate autologous hematopoietic grafts and skin cells with the inherent capacity to treat skin and mucosal erosions that typify this genodermatosis. Journal of Investigative Dermatology (2011) 131, 848-856; doi:10.1038/jid.2010.346; published online 2 December 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据